IM Cannabis (NASDAQ: IMCC) is one of 43 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it contrast to its rivals? We will compare IM Cannabis to similar companies based on the strength of its analyst recommendations, valuation, profitability, risk, earnings, dividends and institutional ownership.
This table compares IM Cannabis and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|IM Cannabis Competitors||-196.99%||-84.80%||-18.10%|
This is a breakdown of recent ratings and price targets for IM Cannabis and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|IM Cannabis Competitors||221||604||580||12||2.27|
IM Cannabis currently has a consensus target price of $8.75, suggesting a potential upside of 165.96%. As a group, “Medicinals & botanicals” companies have a potential upside of 43.87%. Given IM Cannabis’ stronger consensus rating and higher probable upside, equities research analysts clearly believe IM Cannabis is more favorable than its rivals.
Institutional and Insider Ownership
13.7% of IM Cannabis shares are held by institutional investors. Comparatively, 17.9% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 30.9% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares IM Cannabis and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|IM Cannabis||$11.86 million||-$21.42 million||-5.98|
|IM Cannabis Competitors||$220.78 million||-$89.53 million||-16.22|
IM Cannabis’ rivals have higher revenue, but lower earnings than IM Cannabis. IM Cannabis is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
IM Cannabis beats its rivals on 8 of the 12 factors compared.
IM Cannabis Company Profile
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.